Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolson, A.
Right arrow Articles by Smith, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolson, A.
Right arrow Articles by Smith, D. F.
Related Collections
Right arrow Antiepileptic drugs
NEUROLOGY 2004;63:568-570
© 2004 American Academy of Neurology
Brief Communications

A prospective analysis of the outcome of levetiracetam in clinical practice

Andrew Nicolson, MRCP MBChB, Sheila A. Lewis, BSc and David F. Smith, FRCP

From the Department of Neurology (Dr. Nicolson), Hope Hospital, Salford, Wrexham Maelor Hospital (S.A. Lewis), and Walton Centre for Neurology and Neurosurgery (Dr. Smith), Liverpool, UK.

Address correspondence and reprint requests to Dr. Andrew Nicolson, Department of Neurology, Hope Hospital, Stott Lane, Salford M6 8HD, UK; e-mail: andrew{at}nicolson71.freeserve.co.uk

In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period. Two hundred forty-five (69.2%) patients remained on LEV, with 8.8% achieving remission and some improvement in seizure control in 49.3%. Sedation was the most common adverse effect (10.7%), but mood disturbance was more likely to lead to discontinuation (4.8%). Cumulative probability of remaining on LEV at 12 months was 0.74 (95% CI 0.69 to 0.79). Factors predictive of a poorer retention were a greater number of previous antiepileptic drugs and a faster initial titration regimen.

Received December 4, 2003. Accepted in final form March 19, 2004.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Depondt, A W C Yuen, G S Bell, T Mitchell, M J Koepp, J S Duncan, and J W Sander
The long term retention of levetiracetam in a large cohort of patients with epilepsy
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 101 - 103.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.